{"id":1505,"date":"2014-07-04T13:36:10","date_gmt":"2014-07-04T13:36:10","guid":{"rendered":"http:\/\/delveinsightblog.wordpress.com\/?p=22"},"modified":"2022-01-21T18:07:58","modified_gmt":"2022-01-21T12:37:58","slug":"ema-biosimilars-approvals","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals","title":{"rendered":"EMA Biosimilars Approvals"},"content":{"rendered":"\n

In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via the European Medicines Agency (EMA) and not nationally.<\/p>\n\n\n\n

On 27 June 2014, the European Medicines Agency\u2019s (EMA\u2019s) Committee for Medicinal Products for Human Use (CHMP) had recommended granting of marketing authorization for a biosimilar insulin glargine product (LY2963016).<\/p>\n\n\n\n

Eli Lilly and its partner Boehringer Ingelheim has produced the biosimilar insulin glargine, which will be called as Abasria (LY2963016). The drug is a biosimilar of French drugmaker Sanofi\u2019s diabetes drug Lantus (insulin glargine).<\/p>\n\n\n\n

To date, EMA has approved 21 biosimilars within the product classes of human growth hormone, granulocyte colony-stimulating factor, erythropoietin, insulin and TNF-inhibitor, for use in the EU.<\/p>\n\n\n\n

Two biosimilar approvals have been withdrawn; one for filgrastim in April 2011 and one for somatropin in May 2012, leaving a total of 19 biosimilars approved for use in Europe.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\n
Share This post on twitter #Migraine is a medical condition characterized by recurrent headaches that can last from 4 to @abbvie 72 hours and often results in a wide range of symptoms. It is mainly associated with a painful headache <\/h6>\n
\n\nTweet This\n<\/a>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via the European Medicines Agency (EMA) and not nationally. On 27 June 2014, the European Medicines Agency\u2019s (EMA\u2019s) Committee for Medicinal Products for Human Use (CHMP) had recommended granting of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17393,709,17392,17394,17395],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-1505","post","type-post","status-publish","format-standard","hentry","category-articles","tag-biosimilars","tag-ema","tag-ema-biosimilars","tag-eu","tag-tnf-inhibitor","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"\nEMA Biosimilars Approvals - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Biosimilars Approvals - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-07-04T13:36:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-21T12:37:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/EMA-Biosimilars-Approval.jpg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EMA Biosimilars Approvals - DelveInsight Business Research","description":"In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals","og_locale":"en_US","og_type":"article","og_title":"EMA Biosimilars Approvals - DelveInsight Business Research","og_description":"In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved","og_url":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2014-07-04T13:36:10+00:00","article_modified_time":"2022-01-21T12:37:58+00:00","og_image":[{"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/EMA-Biosimilars-Approval.jpg","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals","url":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals","name":"EMA Biosimilars Approvals - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/EMA-Biosimilars-Approval.jpg","datePublished":"2014-07-04T13:36:10+00:00","dateModified":"2022-01-21T12:37:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/ema-biosimilars-approvals#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/23123249\/EMA-Biosimilars-Approval.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/08\/23123249\/EMA-Biosimilars-Approval.jpg","width":300,"height":224},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Biosimilars<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">EMA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">EMA Biosimilars<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">EU<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TNF Inhibitor<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biosimilars<\/span>","<span class=\"advgb-post-tax-term\">EMA<\/span>","<span class=\"advgb-post-tax-term\">EMA Biosimilars<\/span>","<span class=\"advgb-post-tax-term\">EU<\/span>","<span class=\"advgb-post-tax-term\">TNF Inhibitor<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jul 4, 2014","modified":"Updated on Jan 21, 2022"},"absolute_dates_time":{"created":"Posted on Jul 4, 2014 1:36 pm","modified":"Updated on Jan 21, 2022 6:07 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1505"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1505\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1505"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1505"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}